Compass Pathways (Compass Pathways) Cash And Cash Equivalents : $220.20 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Cash And Cash Equivalents?

Compass Pathways's quarterly cash and cash equivalents increased from Jun. 2023 ($148.23 Mil) to Sep. 2023 ($248.04 Mil) but then stayed the same from Sep. 2023 ($248.04 Mil) to Dec. 2023 ($220.20 Mil).

Compass Pathways's annual cash and cash equivalents declined from Dec. 2021 ($273.24 Mil) to Dec. 2022 ($143.21 Mil) but then increased from Dec. 2022 ($143.21 Mil) to Dec. 2023 ($220.20 Mil).

Compass Pathways Cash And Cash Equivalents Historical Data

The historical data trend for Compass Pathways's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Cash And Cash Equivalents Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

24.97

190.33

273.24

143.21

220.20

Compass Pathways Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															143.21	117.10	148.23	248.04	220.20

Compass Pathways Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Compass Pathways (NAS:CMPS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Compass Pathways Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways (Compass Pathways) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

5Y6:Germany

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Executives

Ekaterina Malievskaia	officer: Chief Innovation Officer	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith	director, 10 percent owner, officer: Chief Executive Officer	C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes	officer: Interim CFO	C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath	director, officer: Chief Executive Officer	C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton	director	8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens	officer: General Counsel & CLO	1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Linda Mcgoldrick	director	C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade	director	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin	officer: Chief Medical Officer	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT